OS Animal Health Shows Positive Phase 2 Results for OST-HER2
Rockville, Maryland, June 26, 2026 OS Animal Health announced the peer-reviewed publication of Phase 2 clinical trial results evaluating...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Rockville, Maryland, June 26, 2026 OS Animal Health announced the peer-reviewed publication of Phase 2 clinical trial results evaluating...
INDIANAPOLIS, June 15, 2026 Elanco Animal Health Incorporated has announced that the U.S. Department of Agriculture (USDA) has approved...
INDIANAPOLIS, INDIANA, April 27, 2026 Elanco Animal Health has received Emergency Use Authorization (EUA) from the U.S. Food and...
WASHINGTON, D.C., April 3, 2026 The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) has released its...
INDIANAPOLIS, Ind., October 24, 2025 — In a landmark decision for veterinary medicine and regulatory preparedness, Elanco Animal Health...
